دورية أكاديمية
1143PD - Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)
العنوان: | 1143PD - Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162) |
---|---|
المؤلفون: | Konstantinopoulos, P.A., Sachdev, J.C., Schwartzberg, L., Matulonis, U.A., Sun, P., Wang, J.Y., Guo, W., Bobilev, D., Aktan, G., Karantza, V., Dezube, B., Vinayak, S. |
المصدر: | In Annals of Oncology September 2017 28 Supplement 5:v406-v407 |
قاعدة البيانات: | ScienceDirect |
كن أول من يترك تعليقا!